PMEF
ALXO icon

Point72 Middle East FZE’s ALX Oncology ALXO Stock Holding History

Point72 Middle East FZE’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,815
Closed -$21.8K – 1516
2023
Q1 		$21.8K Buy
4,815
+4,623
+2,408% +$35K ﹤0.01% 1415
2022
Q4 		$2.16K Buy
+192
New +$2.16K ﹤0.01% 1814

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Middle East FZE's ALXO Position: Q2 2023 in Review

Point72 Middle East FZE sold out of ALX Oncology (ALXO) in Q2 2023, closing a stake of 4,815 shares — an estimated $21.8K sold.

Point72 Middle East FZE first reported a position in ALXO in Q4 2022 and held it in 2 quarters. The position peaked at $21.8K in Q1 2023. 75 funds tracked by Wall St. Rank hold ALXO as of Q2 2023.

  • Point72 Middle East FZE reported no remaining ALX Oncology position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 4,815 ALX Oncology shares in Q2 2023, an estimated $21.8K.
  • Point72 Middle East FZE first reported a position in ALX Oncology in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's ALX Oncology position peaked at $21.8K in Q1 2023.
  • 75 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.